Intensive multimodality Treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor

Susan N. Chi, Mary Ann Zimmerman, Xiaopan Yao, Kenneth J Cohen, Peter Burger, Jaclyn A. Biegel, Lucy B. Rorke-Adams, Michael J. Fisher, Anna Janss, Claire Mazewski, Stewart Goldman, Peter E. Manley, Daniel C. Bowers, Anne Bendel, Joshua Rubin, Christopher D. Turner, Karen J. Marcus, Liliana Goumnerova, Nicole J. Ullrich, Mark W. Kieran

Research output: Contribution to journalArticle

Abstract

Purpose Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months. Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT. Patients and Methods Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralum-bar and intraventricular routes. Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis. Results Between 2004 and 2006, 25 patients were enrolled; 20 were eligible for evaluation. Median age at diagnosis was 26 months (range, 2.4 months to 19.5 years). Gross total resection of the primary tumor was achieved in 11 patients. Fourteen patients had M0 disease at diagnosis, one patient had M2 disease, and five patients had M3 disease. Fifteen patients received radiation therapy: 11 focal and four craniospinal. Significant toxicities, in addition to the expected, included radiation recall (n = 2) and transverse myelitis (n = 1). There was one toxic death. Of the 12 patients who were assessable for chemotherapeutic response (pre-RT), the objective response rate was 58%. The objective response rate observed after RT was 38%. The 2-year progression-free and overall survival rates are 53% ± 13% and 70% ± 10%, respectively. Median overall survival has not yet been reached. Conclusion This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.

Original languageEnglish (US)
Pages (from-to)385-389
Number of pages5
JournalJournal of Clinical Oncology
Volume27
Issue number3
DOIs
StatePublished - Jan 20 2009

Fingerprint

Radiotherapy
Therapeutics
Survival
Typical Teratoid Rhabdoid Tumor
Atypical Teratoid Tumor
Transverse Myelitis
Neoplasms
Poisons
Disease-Free Survival
Survival Rate
Maintenance
Radiation
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Intensive multimodality Treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. / Chi, Susan N.; Zimmerman, Mary Ann; Yao, Xiaopan; Cohen, Kenneth J; Burger, Peter; Biegel, Jaclyn A.; Rorke-Adams, Lucy B.; Fisher, Michael J.; Janss, Anna; Mazewski, Claire; Goldman, Stewart; Manley, Peter E.; Bowers, Daniel C.; Bendel, Anne; Rubin, Joshua; Turner, Christopher D.; Marcus, Karen J.; Goumnerova, Liliana; Ullrich, Nicole J.; Kieran, Mark W.

In: Journal of Clinical Oncology, Vol. 27, No. 3, 20.01.2009, p. 385-389.

Research output: Contribution to journalArticle

Chi, SN, Zimmerman, MA, Yao, X, Cohen, KJ, Burger, P, Biegel, JA, Rorke-Adams, LB, Fisher, MJ, Janss, A, Mazewski, C, Goldman, S, Manley, PE, Bowers, DC, Bendel, A, Rubin, J, Turner, CD, Marcus, KJ, Goumnerova, L, Ullrich, NJ & Kieran, MW 2009, 'Intensive multimodality Treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor', Journal of Clinical Oncology, vol. 27, no. 3, pp. 385-389. https://doi.org/10.1200/JCO.2008.18.7724
Chi, Susan N. ; Zimmerman, Mary Ann ; Yao, Xiaopan ; Cohen, Kenneth J ; Burger, Peter ; Biegel, Jaclyn A. ; Rorke-Adams, Lucy B. ; Fisher, Michael J. ; Janss, Anna ; Mazewski, Claire ; Goldman, Stewart ; Manley, Peter E. ; Bowers, Daniel C. ; Bendel, Anne ; Rubin, Joshua ; Turner, Christopher D. ; Marcus, Karen J. ; Goumnerova, Liliana ; Ullrich, Nicole J. ; Kieran, Mark W. / Intensive multimodality Treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 3. pp. 385-389.
@article{1c476701097642bbac63b06045b76265,
title = "Intensive multimodality Treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor",
abstract = "Purpose Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months. Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT. Patients and Methods Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralum-bar and intraventricular routes. Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis. Results Between 2004 and 2006, 25 patients were enrolled; 20 were eligible for evaluation. Median age at diagnosis was 26 months (range, 2.4 months to 19.5 years). Gross total resection of the primary tumor was achieved in 11 patients. Fourteen patients had M0 disease at diagnosis, one patient had M2 disease, and five patients had M3 disease. Fifteen patients received radiation therapy: 11 focal and four craniospinal. Significant toxicities, in addition to the expected, included radiation recall (n = 2) and transverse myelitis (n = 1). There was one toxic death. Of the 12 patients who were assessable for chemotherapeutic response (pre-RT), the objective response rate was 58{\%}. The objective response rate observed after RT was 38{\%}. The 2-year progression-free and overall survival rates are 53{\%} ± 13{\%} and 70{\%} ± 10{\%}, respectively. Median overall survival has not yet been reached. Conclusion This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.",
author = "Chi, {Susan N.} and Zimmerman, {Mary Ann} and Xiaopan Yao and Cohen, {Kenneth J} and Peter Burger and Biegel, {Jaclyn A.} and Rorke-Adams, {Lucy B.} and Fisher, {Michael J.} and Anna Janss and Claire Mazewski and Stewart Goldman and Manley, {Peter E.} and Bowers, {Daniel C.} and Anne Bendel and Joshua Rubin and Turner, {Christopher D.} and Marcus, {Karen J.} and Liliana Goumnerova and Ullrich, {Nicole J.} and Kieran, {Mark W.}",
year = "2009",
month = "1",
day = "20",
doi = "10.1200/JCO.2008.18.7724",
language = "English (US)",
volume = "27",
pages = "385--389",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Intensive multimodality Treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor

AU - Chi, Susan N.

AU - Zimmerman, Mary Ann

AU - Yao, Xiaopan

AU - Cohen, Kenneth J

AU - Burger, Peter

AU - Biegel, Jaclyn A.

AU - Rorke-Adams, Lucy B.

AU - Fisher, Michael J.

AU - Janss, Anna

AU - Mazewski, Claire

AU - Goldman, Stewart

AU - Manley, Peter E.

AU - Bowers, Daniel C.

AU - Bendel, Anne

AU - Rubin, Joshua

AU - Turner, Christopher D.

AU - Marcus, Karen J.

AU - Goumnerova, Liliana

AU - Ullrich, Nicole J.

AU - Kieran, Mark W.

PY - 2009/1/20

Y1 - 2009/1/20

N2 - Purpose Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months. Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT. Patients and Methods Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralum-bar and intraventricular routes. Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis. Results Between 2004 and 2006, 25 patients were enrolled; 20 were eligible for evaluation. Median age at diagnosis was 26 months (range, 2.4 months to 19.5 years). Gross total resection of the primary tumor was achieved in 11 patients. Fourteen patients had M0 disease at diagnosis, one patient had M2 disease, and five patients had M3 disease. Fifteen patients received radiation therapy: 11 focal and four craniospinal. Significant toxicities, in addition to the expected, included radiation recall (n = 2) and transverse myelitis (n = 1). There was one toxic death. Of the 12 patients who were assessable for chemotherapeutic response (pre-RT), the objective response rate was 58%. The objective response rate observed after RT was 38%. The 2-year progression-free and overall survival rates are 53% ± 13% and 70% ± 10%, respectively. Median overall survival has not yet been reached. Conclusion This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.

AB - Purpose Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months. Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT. Patients and Methods Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy. Intrathecal chemotherapy was administered, alternating intralum-bar and intraventricular routes. Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis. Results Between 2004 and 2006, 25 patients were enrolled; 20 were eligible for evaluation. Median age at diagnosis was 26 months (range, 2.4 months to 19.5 years). Gross total resection of the primary tumor was achieved in 11 patients. Fourteen patients had M0 disease at diagnosis, one patient had M2 disease, and five patients had M3 disease. Fifteen patients received radiation therapy: 11 focal and four craniospinal. Significant toxicities, in addition to the expected, included radiation recall (n = 2) and transverse myelitis (n = 1). There was one toxic death. Of the 12 patients who were assessable for chemotherapeutic response (pre-RT), the objective response rate was 58%. The objective response rate observed after RT was 38%. The 2-year progression-free and overall survival rates are 53% ± 13% and 70% ± 10%, respectively. Median overall survival has not yet been reached. Conclusion This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.

UR - http://www.scopus.com/inward/record.url?scp=58549119586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58549119586&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.18.7724

DO - 10.1200/JCO.2008.18.7724

M3 - Article

VL - 27

SP - 385

EP - 389

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -